Brief: Cleo Diagnostics Commences U.S. Regulatory Process With FDA
26/06/2024 02:27
June 26 (Reuters) - Cleo Diagnostics Ltd COV.AX :
* COMMENCES U.S. REGULATORY PROCESS WITH FDA
* COMPLETED AN INITIAL PRE-SUBMISSION MEETING WITH FDA
* OUTLINED ITS SUBMISSION FRAMEWORK AND CLINICAL PLAN FOR
ITS
OVARIAN CANCER DETECTION BLOOD TEST WITH FDA
Further company coverage: COV.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CLEO Diagnostics
See all newsAustralia's Cleo Diagnostics jumps after cancer screening test meets milestone
Brief: Cleo Diagnostics Files Patents For Its Ovarian Cancer Screening Test
Australia's Cleo Diagnostics jumps as ovarian cancer test hits validation milestone
Brief: Cleo Diagnostics Receives First Batch Of Commercially Manufactured Test Kits
Brief: Cleo Diagnostics Raises A$5M